Uganda’s National Drug Authority approved Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention, on January 5, 2025. The drug was developed by US-based Gilead Sciences. Clinical trials showed it prevents HIV infection with 100 per cent effectiveness in high-risk groups. “Uganda’s National Drug Authority has just approved Lenacapavir, a twice-yearly dose of PrEP […]